We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Mechanism Explains Why Females Do Not Make Twice as Much Protein as Males

By Biotechdaily staff writers
Posted on 16 Jun 2008
Researchers working with a fruit fly model have found a mechanism that explains why females with two X chromosomes do not produce twice the amount of proteins than males that have only a single X chromosome. More...
This phenomenon is known as dosage compensation.

Investigators at the European Molecular Biology Laboratory (Heidelberg, DE) and at the EMBL-European Bioinformatics Institute (Hinxton, UK) concentrated on the MSL protein complex, which had been shown previously to mediate dosage compensation in the fruit fly.

They reported in the June 2008 issue of the journal Cell that a protein called MOF, which is the histone H4 lysine 16 (H4K16) specific histone acetyltransferase, is the active component of MSL. MOF's mode of action was traced to differential binding behavior depending on whether the target gene was located on the X chromosome or on the autosomes. On autosomes and the X chromosome in females, MOF bound mostly to the beginning of the gene where transcription starts. On the X chromosome in males, however, MOF bound also towards the end of the gene. This differential binding resulted in relatively greater protein production by the male X chromosome.
"We were very surprised to find MOF bound not only to the X chromosome in males, but also to all the other chromosomes in the nucleus. This suggests the enzyme as a universal regulator of transcription that has evolved to play a specific role in dosage compensation,” said senior author Dr. Asifa Akhtar, a senior researcher at the European Molecular Biology Laboratory.
Although the mechanism of dosage compensation is different in mammals, MOF is conserved across species and has a human homologue. The investigators are keen to discover what functional role this enzyme might play in this context.


Related Links:
European Molecular Biology Laboratory
EMBL-European Bioinformatics Institute

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.